Novartis Pauses Cell Therapy Trials After Three Deaths as MS Pill Succeeds in Late-Stage Studies

Three deaths halt Novartis rap-cel trials in autoimmune disease. Positive Phase 3 data for remibrutinib in relapsing MS announced the same day.